<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.1d3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">71154</article-id><article-id pub-id-type="doi">10.7554/eLife.71154</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Stem Cells and Regenerative Medicine</subject></subj-group></article-categories><title-group><article-title>Skeletal dysplasia-causing TRPV4 mutations suppress the hypertrophic differentiation of human iPSC-derived chondrocytes</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-242470"><name><surname>Dicks</surname><given-names>Amanda R</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-142287"><name><surname>Maksaev</surname><given-names>Grigory I</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-242471"><name><surname>Harissa</surname><given-names>Zainab</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-242472"><name><surname>Savadipour</surname><given-names>Alireza</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-148418"><name><surname>Tang</surname><given-names>Ruhang</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-242477"><name><surname>Steward</surname><given-names>Nancy</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-242473"><name><surname>Liedtke</surname><given-names>Wolfgang</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-22774"><name><surname>Nichols</surname><given-names>Colin G</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-4929-2134</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-242474"><name><surname>Wu</surname><given-names>Chia-Lung</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-9598-7036</contrib-id><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="par-4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-147279"><name><surname>Guilak</surname><given-names>Farshid</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-7380-0330</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="other" rid="par-3"/><xref ref-type="fn" rid="conf3"/></contrib><aff id="aff1"><institution content-type="dept">Department of Biomedical Engineering</institution>, <institution>Washington University in St. Louis</institution>, <addr-line><named-content content-type="city">St Louis</named-content></addr-line>, <country>United States</country></aff><aff id="aff2"><institution content-type="dept">Department of Cell Biology and Physiology</institution>, <institution>Washington University in St. Louis</institution>, <addr-line><named-content content-type="city">St Louis</named-content></addr-line>, <country>United States</country></aff><aff id="aff3"><institution content-type="dept">Department of Orthopedic Surgery</institution>, <institution>Washington University in St. Louis</institution>, <addr-line><named-content content-type="city">St Louis</named-content></addr-line>, <country>United States</country></aff><aff id="aff4"><institution>Regeneron Pharmaceuticals</institution>, <addr-line><named-content content-type="city">Tarrytown</named-content></addr-line>, <country>United States</country></aff><aff id="aff5"><institution content-type="dept">Department of Orthopaedics and Rehabilitation</institution>, <institution>University of Rochester</institution>, <addr-line><named-content content-type="city">Rochester</named-content></addr-line>, <country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-171310"><name><surname>Chen</surname><given-names>Di</given-names></name><role>Reviewing editor</role><aff><institution>Chinese Academy of Sciences</institution>, <country>China</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>guilak@wustl.edu</email> (FG);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>22</day><month>02</month><year>2023</year></pub-date><volume>12</volume><elocation-id>e71154</elocation-id><history><date date-type="received"><day>10</day><month>06</month><year>2021</year></date><date date-type="accepted"><day>03</day><month>02</month><year>2023</year></date></history><permissions><copyright-statement>Â© 2023, Dicks et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Dicks et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-71154-v1.pdf"/><abstract><p>Mutations in the TRPV4 ion channel can lead to a range of skeletal dysplasias. However, the mechanisms by which TRPV4 mutations lead to distinct disease severity remain unknown. Here, we use CRISPR-Cas9-edited human induced pluripotent stem cells (hiPSCs) harboring either the mild V620I or lethal T89I mutations to elucidate the differential effects on channel function and chondrogenic differentiation. We found that hiPSC-derived chondrocytes with the V620I mutation exhibited increased basal currents through TRPV4. However, both mutations showed more rapid calcium signaling with a reduced overall magnitude in response to TRPV4 agonist GSK1016790A compared to wildtype. There were no differences in overall cartilaginous matrix production, but the V620I mutation resulted in reduced mechanical properties of cartilage matrix later in chondrogenesis. mRNA sequencing revealed that both mutations upregulated several anterior <italic>HOX</italic> genes and downregulated antioxidant genes <italic>CAT</italic> and <italic>GSTA1</italic> throughout chondrogenesis. BMP4 treatment upregulated several essential hypertrophic genes in WT chondrocytes; however, this hypertrophic maturation response was inhibited in mutant chondrocytes. These results indicate that the TRPV4 mutations alter BMP signaling in chondrocytes and prevent proper chondrocyte hypertrophy, as a potential mechanism for dysfunctional skeletal development. Our findings provide potential therapeutic targets for developing treatments for TRPV4-mediated skeletal dysplasias.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>AG15768</award-id><principal-award-recipient><name><surname>Guilak</surname><given-names>Farshid</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>AG46927</award-id><principal-award-recipient><name><surname>Guilak</surname><given-names>Farshid</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>ar072999</award-id><principal-award-recipient><name><surname>Guilak</surname><given-names>Farshid</given-names></name></principal-award-recipient></award-group><award-group id="par-4"><funding-source><institution-wrap><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>AR075899</award-id><principal-award-recipient><name><surname>Wu</surname><given-names>Chia-Lung</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf2"><p>Wolfgang Liedtke, Patents on TRPV4 inhibitors have been licensed to TRPblue.  Dr. Liedtke is an employee of Regeneron Pharmaceuticals.(US Patents 9,701,675; 10,329,265; and 11,014,896)..</p></fn><fn fn-type="conflict" id="conf3"><p>Farshid Guilak, Patents on TRPV4 inhibitors licensed to TRPblue Inc. (US Patents 9,701,675; 10,329,265; and 11,014,896)..</p></fn><fn fn-type="conflict" id="conf1"><p>The other authors declare that no competing interests exist.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>All RNAseq data files generated and reported in this study are available on GEO (accession number GSE225446, https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE225446).</p><p>The following datasets were generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><collab>Dicks AR</collab><collab>Maksaev GI</collab><collab>Harissa Z</collab><collab>Savadipour A</collab><collab>Tang R</collab><collab>Steward N</collab><collab>Liedtke W</collab><collab>Nichols CG</collab><collab>Wu C</collab><collab>Guilak F</collab></person-group><year iso-8601-date="2023">2023</year><source>Skeletal dysplasia-causing TRPV4 mutations suppress the hypertrophic differentiation of human iPSC-derived chondrocytes</source><ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE225446">https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE225446</ext-link><comment>GSE225446</comment></element-citation></p></sec><supplementary-material><ext-link xlink:href="elife-71154-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>